You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 148 No. 4, April 1988 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

National Adverse Drug Reaction Surveillance

1986

Gerald A. Faich, MD, MPH; Michael Dreis, RPh, MPH; Dianne Tomita, MPH

Arch Intern Med. 1988;148(4):785-787.


Abstract

• The collection of adverse drug reaction (ADR) reports by the Food and Drug Administration serves to provide additional information on the toxic reactions of drugs that often cannot be known before a drug is marketed. In 1986, a total of 53 547 ADR reports were received; 56% of these were made by US health care professionals based on observations made during usual clinical practice. The 1986 total represents an increase of 14% in ADR reporting over 1985, continuing a trend begun in 1981. While these increases are encouraging, US reporting rates are far below many other countries, and further encouragement of reporting must be done. Of these ADR reports, 24% involved serious reactions and 20% involved new drugs. An ADR report should be seen as a professional responsibility; reports are carefully analyzed and used.

(Arch Intern Med 1988;148:785-787)



Author Affiliations

From the Office of Epidemiology and Biostatistics, Center for Drug Evaluation, US Food and Drug Administration, Rockville, Md.


Footnotes

Accepted for publication Dec 28, 1987.

The views expressed herein are those of the authors and are not to be construed as official, or as reflecting the views of the US Food and Drug Administration.

Reprints not available.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antiepileptics in the Elderly: Pharmacoepidemiology and Pharmacokinetics
Cloyd et al.
Arch Fam Med 1994;3:589-598.
ABSTRACT  

Uses of Nonsteroidal Anti-inflammatory Drugs in Pediatrics
Lindsley
Arch Pediatr Adolesc Med 1993;147:229-236.
ABSTRACT  

Recognizing Hospital Adverse Drug Reactions
Savitsky
Journal of Pharmacy Practice 1989;2:203-208.
ABSTRACT  

Adverse Drug Reactions and the Food and Drug Administration
Pearson and Kennedy
Journal of Pharmacy Practice 1989;2:209-213.
ABSTRACT  

Implementing a Hospital-Based Adverse Drug Reaction Reporting Program
Miwa
Journal of Pharmacy Practice 1989;2:214-220.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1988 American Medical Association. All Rights Reserved.